Daily Intake of 1000 mg Vitamin C Boosts Survival in Patients with Pre-Cancerous Blood Disorders

EVITA Clinical Trial Insights

According to НВ — Техно: The EVITA clinical trial, involving 109 patients diagnosed with pre-cancerous blood conditions, revealed that a daily dose of 1000 mg vitamin C over a one-year period was linked to improved survival rates and fewer adverse effects compared to placebo. This research was carried out by an international team from the Van Andel Research Institute and the University of Copenhagen.

Patient Diagnoses and Study Outcomes

Participants were diagnosed primarily with clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS). At the start, over half of the patients exhibited insufficient vitamin C levels. Supplementation successfully restored normal blood vitamin C concentrations in those receiving the vitamin. However, the study did not find a statistically significant reduction in the progression rate of abnormal blood cell accumulation.

Researchers also observed shifts in cytokine levels, which may be connected to potentially beneficial treatment effects. Vitamin C plays a role in supporting the enzyme TET2, which is critical for gene regulation and cell development. Mutations in TET2 are frequently present in leukemia and other blood disorders.

Currently, no definitive methods exist to prevent the progression of CCUS to leukemia, and stem cell transplantation is not a viable option for all patients with myelodysplastic syndrome. The research team intends to continue analyzing EVITA’s findings in a forthcoming phase three clinical trial.

“These findings cautiously raise hope for enhancing care of patients with pre-cancerous blood diseases,” stated Professor Peter Jones from the Van Andel Research Institute.

Meanwhile, study leader Kirsten Grønbæk emphasized, “It is premature to draw firm conclusions or recommend vitamin C supplementation at this stage.”

The EVITA trial opens promising avenues for treating individuals with pre-cancerous blood disorders, highlighting the significance of vitamin C in maintaining patient health. Despite encouraging results, experts urge caution and call for further research to confirm the vitamin’s safety and effectiveness in this patient group. Continued investigation may pave the way for new therapeutic strategies, particularly important for those ineligible for stem cell transplantation.

As researchers explore innovative treatment options, recent advancements in drug development are also gaining attention. For instance, scientists at the University of Chicago have developed a method to replace carbon with nitrogen in drug molecules using blue light. This groundbreaking technique could potentially enhance the efficacy of various medications, paralleling the ongoing efforts to improve care for patients with pre-cancerous blood disorders. To learn more about this exciting research, visit this article.